From injections to pills: oral peptides set to transform drug development
Drug Target Review
AUGUST 12, 2025
For example, orally bioavailable PCSK9 inhibitor, Enlicitide (MK-0616), is currently in Phase III trials for treatment of adult hypercholesterolemia. Similarly, Icotrokinra (JNJ-2113), 4 an orally administered peptide-based treatment for psoriasis, is currently also in Phase III trials.
Let's personalize your content